Skip to main content

Outbreak of West Nile Virus May Be Worst Ever


August 22, 2012 — An outbreak of West Nile virus infections that has claimed more than 3 dozen lives this year could shape up to be worst ever, the US Centers for Disease Control and Prevention (CDC) announced today.
The number of reported cases jumped in just a week's time from 693, as of August 14, to 1118, as of August 21, according to the agency. During that same period, the number of reported deaths rose from 26 to 41.
"We're in the midst of one of the largest outbreaks of West Nile virus ever seen," said Lyle Petersen, MD, MPH, director of the CDC's Division of Vector-Borne Infectious Diseases, in a press briefing today. The number of disease cases reported in 2012 through August 21 is the highest for this time frame since the mosquito-borne virus was first detected in the United States in 1999.
West Nile virus infections typically peak in mid-August, but the CDC expects the case count to continue rising through the end of September because of delays in the cases getting reported, said Dr. Petersen. "It takes a couple of weeks for [an infected] person to get sick, go to the doctor, and get reported."
If the case count stays on its current trajectory through year's end, he said, "this will be among the biggest or the biggest outbreak."
Texas is the epicenter of the outbreak, with 537 reported cases and 19 deaths — nearly half of the nationwide totals. Last week the mayor of hard-hit Dallas declared a state of emergency as a prelude to aerial spraying of insecticide to kill off mosquitos. The only states not to report West Nile virus infections so far are Alaska, Hawaii, and Vermont.
Dr. Petersen said it is not clear why 2012 is a bad year for the West Nile virus, but the heat wave that has scorched much of the country is a likely suspect.
"One observation that has occurred in the United States and elsewhere is that hot weather seems to promote West Nile virus outbreaks," he said. Lab experiments show that higher temperatures increase the transmissibility of the virus through mosquitos.
Fever Cases "Very Underreported"
For the 1118 cases of West Nile virus infection reported through August 21, roughly 44% of patients had fever while the rest contracted neuroinvasive diseases — in particular, encephalitis and meningitis. The death rate for infected individuals with neuroinvasive diseases is 10%. Survivors often struggle with neurological or cognitive problems for years.
The proportion of reported cases with neuroinvasive diseases is misleading because the fever cases "are very underreported," Dr. Petersen said. Only 1 in 150 individuals infected with the virus develop a neuroinvasive disease, but almost all of them end up in the hospital. In contrast, up to 20% of infected individuals experience fever and other symptoms considered milder than neuroinvasive disease, but many of them never bother to consult a clinician. When they do, clinicians may not diagnose a West Nile virus infection. In addition, the CDC does not recommend routine testing for infections presenting with fever.
"The most important data we have is for neuroinvasive-disease cases," Dr. Petersen said. "We do believe they're reasonably reported."
The remaining 80% of individuals who acquire the virus experience no symptoms whatsoever.
So far, public health authorities can battle the outbreak only by spraying mosquitos with insecticide and reminding Americans to take precautions such as using insect repellent and emptying standing water from outdoor buckets and similar places where mosquitos might breed. There is no vaccine against the virus, nor any treatment, other than supportive measures such as hospitalization, intravenous fluids, respiratory support, and prevention of secondary infections for those with more severe forms of the viral infection, according to the CDC.

Comments

Post a Comment

Popular posts from this blog

Antidepressants Linked to Higher Diabetes Risk in Kids

Pediatric patients who use antidepressants may have an elevated risk for type 2 diabetes, the authors of a new study report. In a retrospective cohort study of more than 119,000 youths 5 to 20 years of age, the risk for incident type 2 diabetes was nearly twice as high among current users of certain types of antidepressants as among former users, Mehmet Burcu, PhD, and colleagues report in an article  published online October 16 in  JAMA Pediatrics . The risk intensified with increasing duration of use, greater cumulative doses, and higher daily doses of these antidepressants. The findings point to a growing need for closer monitoring of these products, including greater balancing of risks and benefits, in the pediatric population, the authors caution. They undertook the study because, despite growing evidence of an association between antidepressant use and an increased risk for type 2 diabetes in adults, similar research in pediatric patients was scarce. "To our know...
Post a Comment
Read more

Contact Precautions May Have Unintended Consequences

Contact precautions, including gloves, gowns, and isolated rooms, have helped stem the transmission of hospital pathogens but have also had some negative consequences, according to findings from a new study. Healthcare worker (HCWs) visited patients on contact precautions less frequently than other patients and spent less time with those patients when they did visit, report Daniel J. Morgan, MD, from the University of Maryland School of Medicine and the Veterans Affairs (VA) Maryland Health Care System, Baltimore, and colleagues. Moreover, patients on contact precautions also received fewer outside visitors. "Less contact with HCWs suggests that other unintended consequences of contact precautions still exist," Dr. Morgan and coauthors write. "The resulting decrease in HCW contact may lead to increased adverse events and a lower quality of patient care due to less consistent patient monitoring and poorer adherence to standard adverse event prevention methods (such...
Post a Comment
Read more

Missing Data Lead FDA Panel to Vote Against Rivaroxaban for ACS May 23, 2012 (Updated May 24, 2012) (Silver Spring, Maryland) — The missing data issues plaguing the ATLAS ACS 2 TIMI 51 trial of the factor Xa inhibitor rivaroxaban (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the FDA Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting, the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus clopidogrel, or ticlopidine. Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the ATLAS ACS TIMI 46 phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the risk of bleeding and intracranial hemorrhage, but the studies were hindered by early patient withdrawals and missing data. We Don't Know What We're Missing Based on the ATLAS ACS 2 results, FDA reviewer Dr Karen Hicks recommended approval of rivaroxaban for the requested indications except all-cause mortality. However, another FDA reviewer, Dr Thomas Marciniak, was adamant that the trial results are not interpretable because about 12% of the patients had incomplete follow-up, far higher than the 1% to 1.5% differences in the end-point rates between rivaroxaban and placebo. A total of 1294 subjects discontinued the trial prematurely, and the company was only able to contact 183, of which 177 were confirmed to be alive. Because of the patient dropouts, the company adopted a "modified intention-to-treat analysis," whereby patients were observed for 30 days after randomization or the global end date for the trial, instead of observing all the patients until the end of the trial as the FDA originally suggested. Marciniak criticized the sponsor's efforts to follow the patients and said that three patient deaths not counted in the modified intention-to-treat analysis may just be the "tip of the iceberg." Because the percentage of patients whose ultimate vital status remains unknown is much greater than the reported differences in mortality rates, the claimed mortality benefits are not reliable. The majority of the panel sided with Marciniak. For example, Dr Sanjay Kaul (University of California, Los Angeles) voted "no" because "there was enough uncertainty in the quality and robustness of the data that dissuaded me from voting yes. . . . The 'missingness' of the data doesn't invalidate it, but it certainly makes it hard to infer [the conclusion]." Dr Steven Nissen (Cleveland Clinic, OH) said that the decision to use the modified intention-to-treat analysis had a "profound impact" on the interpretability of the data. "It's saying we don't care what happens after 30 days, [and] that colored the trial in ways we couldn't recover from." Given the risk of major bleeding, "I want to see better evidence that this strategy of adding an Xa inhibitor or a direct thrombin inhibitor or something else to a good antiplatelet agent is robustly better for the patient," Nissen said. He recommends that the companies run a new trial of the 2.5 twice-daily dose of rivaroxaban using a strict intention-to-treat approach, but, he said, "I don't expect the death benefit to be too robust." Several panelists said they were concerned that the patients who dropped out of the trial were disproportionately likely to have a bleeding event, which led them to quit the trial, or a "protopathic" event, as statistician Dr Scott Emerson (University of Washington, Seattle) put it. "We're worried that an impending event is what is changing their behavior. We see that all the time in clinical trials--that regularly measured end points do not pick up [all of] the events," he said. He said that since the company was only able to contact 183 of the over 1200 patients who dropped out, it is possible that the dropouts skew the outcomes comparison of the trial. "Differential event rates after dropout are the number-one thing we're afraid of, so you have to explore it" in a statistical sensitivity analysis of the potential impact of these unknown outcomes. "It would not surprise me if, at the end of the day, these data did not hold up under a proper sensitivity analysis," he said. "What I want to know is, among the people who had events, how differential was the follow-up, but I can tell you by just looking at it, there was a very slightly different amount of follow-up of the people in the treatment arm. But I don't know whether everyone in the treatment arm was cured and they were trekking in the Himalayas and everyone in the placebo arm went home to die. I don't know that that's not the case." Dr Maury Krantz (University of Colorado, Denver) voted in favor of approval but said he does not know how rivaroxaban would perform in general clinical practice, especially when used with aspirin and clopidogrel. "I felt very much torn by this. This isn't a simple paradigm shift. It means going to triple therapy, which is really a three-headed monster in many ways. I think that what you're going to see in practice, if this is not done carefully with the proper labeling and secondary studies, is really dramatic magnification of bleeding and perhaps minimization of the efficacy benefit."

May 23, 2012   (Updated May 24, 2012)  (Silver Spring, Maryland)  —  The missing data issues plaguing the  ATLAS ACS 2 TIMI 51   trial of the factor Xa inhibitor  rivaroxaban  (Xarelto, Bayer Healthcare/Janssen Pharmaceuticals) have prevented the drug from earning the endorsement of the  FDA  Cardiovascular and Renal Drugs Advisory Committee. At its May 23 meeting , the panel voted six to four (with one abstention) against recommending that the FDA approve rivaroxaban for reducing the risk of thrombotic cardiovascular events in patients with acute coronary syndrome or unstable angina in combination with aspirin, aspirin plus  clopidogrel , or  ticlopidine . Janssen's application is based on the results of the ATLAS ACS 2 phase 3 and the  ATLAS ACS TIMI 46   phase 2 trial. The placebo-controlled ATLAS ACS 2 showed rivaroxaban reduced the risk of both all-cause and cardiovascular mortality while increasing the ri...
Post a Comment
Read more